Androgen replacement in women: a commentary.

There is increasing evidence to suggest that many postmenopausal women experience symptoms alleviated by androgen therapy and that such symptoms may be secondary to androgen deficiency. Affected women complain of fatigue, low libido, and diminished well-being, symptoms easily and frequently attributed to psychosocial and environmental factors. When such symptoms occur in the setting of low circulating bioavailable testosterone, testosterone replacement results in significant improvement in symptomatology and, hence, quality of life for the majority of women. Whether the apparent therapeutic effects of testosterone replacement are mediated by testosterone and its metabolite 5alpha- dihydrotestosterone or are a consequence of aromatization to estrogen is not known. Despite the paucity of data regarding its effects, inclusion of testosterone in postmenopausal hormone replacement regimens is not uncommon and is likely to become more widespread with the availability of preparations developed specifically for women. Other novel and even more controversial potential indications for androgen therapy in women are currently being evaluated. These include use in women with premature ovarian failure, premenopausal androgen deficiency symptoms, postmenopausal and glucocorticosteroid-related bone loss, alleviation of wasting syndrome secondary to human immunodeficiency virus infection, and management of premenstrual syndrome. The aim of this commentary is to very briefly review the rationale for the use of testosterone in women, create awareness of some of the therapeutic options available in various countries, and stimulate discussion of this important aspect of women's health.

[1]  Frederick C W Wu,et al.  WHICH ANDROGEN REPLACEMENT THERAPY FOR WOMEN , 1999 .

[2]  H. Burger,et al.  The rationale for physiological testosterone replacement in women. , 1998, Bailliere's clinical endocrinology and metabolism.

[3]  D. Schoenfeld,et al.  Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. , 1998, The Journal of clinical endocrinology and metabolism.

[4]  H. Burger,et al.  Should women be treated with testosterone? , 1998, Clinical endocrinology.

[5]  S. Davis The clinical use of androgens in female sexual disorders. , 1998, Journal of sex & marital therapy.

[6]  S. Cummings,et al.  Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. , 1998, The Journal of clinical endocrinology and metabolism.

[7]  G G Klee,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Relationship of Serum Sex Steroid Levels and Bone Turnover Markers with Bone Mineral Density in Men and Women: A Key Role for Bioavailable Estroge , 2022 .

[8]  T. Su,et al.  Pituitary–adrenal hormones and testosterone across the menstrual cycle in women with premenstrual syndrome and controls , 1998, Biological Psychiatry.

[9]  E. Simpson,et al.  Aromatase expression of human osteoblast-like cells , 1998, Molecular and Cellular Endocrinology.

[10]  E. Engleman,et al.  Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. , 1998, The Journal of rheumatology.

[11]  L. Nelson,et al.  Bone Loss in Young Women With Karyotypically Normal Spontaneous Premature Ovarian Failure , 1998, Obstetrics and gynecology.

[12]  J. D. Wagner,et al.  Esterified estrogens with and without methyltestosterone decrease arterial LDL metabolism in cynomolgus monkeys. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[13]  J. Jacobs,et al.  Androgens as adjuvant treatment in postmenopausal female patients with rheumatoid arthritis. , 1996, Annals of the rheumatic diseases.

[14]  H. Burger,et al.  Clinical review 82: Androgens and the postmenopausal woman. , 1996, The Journal of clinical endocrinology and metabolism.

[15]  N. Santoro,et al.  Evidence for diminished midcycle ovarian androgen production in older reproductive aged women. , 1996, Fertility and sterility.

[16]  Wilder Rl Adrenal and gonadal steroid hormone deficiency in the pathogenesis of rheumatoid arthritis. , 1996 .

[17]  O. Ylikorkala,et al.  High bone density in hyperandrogenic women: effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement. , 1996, The Journal of clinical endocrinology and metabolism.

[18]  M. Adams,et al.  Methyltestosterone Does Not Diminish the Beneficial Effects of Estrogen Replacement Therapy on Coronary Artery Reactivity in Cynomolgus Monkeys , 1996 .

[19]  C. Slemenda,et al.  Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women. , 1996, The Journal of clinical investigation.

[20]  R. Wilder Adrenal and gonadal steroid hormone deficiency in the pathogenesis of rheumatoid arthritis. , 1996, The Journal of rheumatology. Supplement.

[21]  S. Schwartz,et al.  Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. , 1996, The Journal of clinical endocrinology and metabolism.

[22]  B. Winblad,et al.  Estradiol and testosterone in specific regions of the human female brain in different endocrine states , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[23]  A. Masi,et al.  Hormonal and pregnancy relationships to rheumatoid arthritis: convergent effects with immunologic and microvascular systems. , 1995, Seminars in arthritis and rheumatism.

[24]  D. Horsfall,et al.  Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Secreto,et al.  Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[26]  N. Watts,et al.  Comparison of Oral Estrogens and Estrogens Plus Androgen on Bone Mineral Density, Menopausal Symptoms, and Lipid‐Lipoprotein Profiles in Surgical Menopause , 1995, Obstetrics and gynecology.

[27]  H. Burger,et al.  Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. , 1995, Maturitas.

[28]  W. Rosner,et al.  Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. , 1995, The Journal of clinical endocrinology and metabolism.

[29]  J. Born,et al.  Selective influence of menstrual cycle on perception of stimuli with reproductive significance. , 1994, Psychosomatic medicine.

[30]  L. Speroff,et al.  A Comparison of Esterified Estrogens With and Without Methyltestosterone: Effects on Endometrial Histology and Serum Lipoproteins in Postmenopausal Women , 1993, Obstetrics and gynecology.

[31]  C. Roselli,et al.  Aromatase activity in the rat brain: Hormonal regulation and sex differences , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[32]  M. Savvas,et al.  Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in post-menopausal women who have previously received long-term oral oestrogens. , 1993, British journal of obstetrics and gynaecology.

[33]  G. Bachmann,et al.  Sexuality in sexagenarian women. , 1991, Maturitas.

[34]  M. Horowitz,et al.  Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic postmenopausal women. , 1989, Archives of internal medicine.

[35]  C. Mortimer,et al.  Skeletal effects of oestrogen and testosterone in postmenopausal women , 1988, BMJ.

[36]  H. Burger,et al.  Effect of combined implants of oestradiol and testosterone on libido in postmenopausal women: , 1987 .

[37]  R. Mathur,et al.  The effect of estrogen treatment on plasma concentrations of steroid hormones, gonadotropins, prolactin and sex hormone-binding globulin in post-menopausal women. , 1985, Maturitas.

[38]  B. Sherwin,et al.  Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. , 1985, Psychosomatic medicine.

[39]  R. Bryan,et al.  Androgen receptors in breast cancer , 1984, Cancer.

[40]  H. Burger,et al.  The management of persistent menopausal symptoms with oestradiol-testosterone implants: clinical, lipid and hormonal results. , 1984, Maturitas.

[41]  D. Rubinow,et al.  Premenstrual syndromes: overview from a methodologic perspective. , 1984, The American journal of psychiatry.

[42]  G. Strain,et al.  Sex differences in the twenty-four-hour mean plasma concentrations of dehydroisoandrosterone (DHA) and dehydroisoandrosterone sulfate (DHAS) and the DHA to DHAS ratio in normal adults. , 1980, The Journal of clinical endocrinology and metabolism.

[43]  H. Jacobs,et al.  PLASMA HORMONE PROFILES IN POST‐MENOPAUSAL WOMEN BEFORE AND DURING OESTROGEN THERAPY , 1977 .

[44]  S. Campbell,et al.  Oestrogen therapy and the menopausal syndrome. , 1969, Clinics in obstetrics and gynaecology.

[45]  H. Judd HORMONAL DYNAMICS ASSOCIATED WITH THE MENOPAUSE , 1976, Clinical obstetrics and gynecology.

[46]  G. Abraham Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle. , 1974, The Journal of clinical endocrinology and metabolism.

[47]  Utian Wh The true clincal features of postmenopause and oöphorectomy, and their response to oestrogen therapy. , 1972 .

[48]  W. Utian The true clincal features of postmenopause and oöphorectomy, and their response to oestrogen therapy. , 1972, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[49]  S. Yrarrázaval,et al.  [The climacteric]. , 1957, Revista medica de Chile.